Pure Global AI
NCT06238817Not yet recruiting

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Incyte CorporationPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
Ruxolitinib Cream
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Incyte Corporation
Timeline & enrollment
Phase
Phase 3
Start date
Apr 06, 2024
End date
Oct 30, 2025
Enrollment
225 participants
Primary outcome

VC Period: Proportion of participants who achieved Eczema Area and Severity Index 75 (EASI75),VC Period: Proportion of participants who achieved Investigator's Global Assessment Treatment Success (IGA-TS)

Summary

This study is being conducted to establish the efficacy of ruxolitinib cream in participants
 with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated
 to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06238817
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06238817 through Pure Global AI's free database. This Phase 3 trial is sponsored by Incyte Corporation and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 225 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.